Free Trial

argenx (ARGX) Competitors

$367.07
+6.05 (+1.68%)
(As of 05/24/2024 ET)

ARGX vs. BNTX, NBIX, TECH, QGEN, RGEN, BIIB, PCVX, RVMD, EXEL, and HALO

Should you be buying argenx stock or one of its competitors? The main competitors of argenx include BioNTech (BNTX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), Biogen (BIIB), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), and Halozyme Therapeutics (HALO). These companies are all part of the "biological products, except diagnostic" industry.

argenx vs.

BioNTech (NASDAQ:BNTX) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

BioNTech has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNTech$4.13B5.58$1.01B$0.50193.90
argenx$1.27B17.20-$295.05M-$5.66-64.85

BioNTech has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 2.4% of argenx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, BioNTech had 19 more articles in the media than argenx. MarketBeat recorded 23 mentions for BioNTech and 4 mentions for argenx. BioNTech's average media sentiment score of 1.32 beat argenx's score of 0.65 indicating that argenx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioNTech
8 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
argenx
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BioNTech presently has a consensus price target of $111.70, suggesting a potential upside of 15.21%. argenx has a consensus price target of $524.68, suggesting a potential upside of 42.94%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe argenx is more favorable than BioNTech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNTech
1 Sell rating(s)
6 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
argenx
1 Sell rating(s)
5 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
2.71

BioNTech has a net margin of 4.01% compared to BioNTech's net margin of -22.58%. argenx's return on equity of 0.55% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
BioNTech4.01% 0.55% 0.49%
argenx -22.58%-14.14%-12.71%

argenx received 485 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 65.86% of users gave argenx an outperform vote while only 42.59% of users gave BioNTech an outperform vote.

CompanyUnderperformOutperform
BioNTechOutperform Votes
115
42.59%
Underperform Votes
155
57.41%
argenxOutperform Votes
600
65.86%
Underperform Votes
311
34.14%

Summary

argenx beats BioNTech on 10 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARGX vs. The Competition

MetricargenxBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$21.81B$2.94B$5.15B$8.05B
Dividend YieldN/A2.23%2.84%3.96%
P/E Ratio-64.8510.34101.3814.47
Price / Sales17.20268.682,486.1071.55
Price / CashN/A162.0635.8231.15
Price / Book5.306.495.364.56
Net Income-$295.05M-$46.01M$106.36M$214.00M
7 Day Performance0.34%-2.68%-1.27%-1.04%
1 Month Performance-0.42%7.71%3.24%3.84%
1 Year Performance-8.48%5.23%5.19%8.60%

argenx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BNTX
BioNTech
0.9741 of 5 stars
$92.07
-0.4%
$111.70
+21.3%
-12.7%$21.89B$4.13B184.146,133Analyst Forecast
Options Volume
Analyst Revision
News Coverage
NBIX
Neurocrine Biosciences
4.6867 of 5 stars
$140.55
-0.8%
$148.96
+6.0%
+50.5%$14.14B$1.89B38.721,400Insider Selling
Positive News
TECH
Bio-Techne
3.9912 of 5 stars
$82.68
+0.2%
$80.50
-2.6%
-1.2%$13.03B$1.14B65.623,050Analyst Downgrade
QGEN
Qiagen
4.2179 of 5 stars
$45.02
-1.0%
$50.95
+13.2%
-6.8%$10.27B$1.97B30.195,967Analyst Revision
RGEN
Repligen
4.3967 of 5 stars
$166.90
-2.8%
$197.75
+18.5%
-4.3%$9.33B$638.76M667.611,783Insider Selling
Analyst Revision
News Coverage
BIIB
Biogen
4.8884 of 5 stars
$227.69
-1.7%
$288.46
+26.7%
-27.8%$33.15B$9.84B28.437,570Analyst Forecast
News Coverage
PCVX
Vaxcyte
0.6844 of 5 stars
$73.65
-3.0%
$78.50
+6.6%
+35.0%$8.01BN/A-17.21254Insider Selling
Positive News
RVMD
Revolution Medicines
3.8064 of 5 stars
$39.66
-0.9%
$43.20
+8.9%
+44.4%$6.54B$11.58M-10.58378Positive News
EXEL
Exelixis
4.9735 of 5 stars
$21.02
-0.2%
$26.13
+24.3%
+6.4%$6.37B$1.83B32.841,310Insider Selling
HALO
Halozyme Therapeutics
4.6055 of 5 stars
$45.54
+1.3%
$53.14
+16.7%
+31.0%$5.80B$829.25M18.82373Analyst Forecast
Insider Selling

Related Companies and Tools

This page (NASDAQ:ARGX) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners